at San Francisco, California and other locations
study started
estimated completion:



The Opsumit Users registry (OPUS; NCT02126943) was developed to characterize the safety profile of Opsumit and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing setting. It is expected that the recruitment target of the OPUS registry cannot be achieved within the planned time period (5000 Opsumit new users by October 2018). The OrPHeUS study is designed to supplement the OPUS registry with retrospectively identified first-time Opsumit users in order to achieve the desired sample size.

Official Title

Multicenter, Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States


Pulmonary Arterial Hypertension Hypertension Familial Primary Pulmonary Hypertension Macitentan Notapplicable


You can join if…

  • Patients who initiated Opsumit for the first time between 19 October 2013 and 31 December 2016 (inclusive)
  • Patients whose medical charts are available for data collection

You CAN'T join if...

  • Patient participation in the OPUS registry
  • Patient participation in any clinical trial involving Opsumit treatment or macitentan investigational product


  • UCSF School of Medicine
    San Francisco California 94143 United States
  • Santa Barbara Cottage Hospital
    Santa Barbara California 93105 United States
  • David Geffen School of Medicine at University of California Los Angeles
    Los Angeles California 90095-1690 United States
  • University of Southern California
    Los Angeles California 90033 United States
  • Loma Linda University Medical Center
    Loma Linda California 92354 United States
  • Paloma Medical Group
    San Juan Capistrano California 92675 United States


in progress, not accepting new patients
Start Date
Completion Date
Study Type
Last Updated
July 19, 2018